- Home
- SAFE vs NTLA Comparison
SAFE vs NTLA Comparison
Compare SAFE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- NTLA
- Stock Information
- Founded
- SAFE 2016
- NTLA 2014
- Country
- SAFE United States
- NTLA United States
- Employees
- SAFE N/A
- NTLA N/A
- Industry
- SAFE Real Estate Investment Trusts
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SAFE Real Estate
- NTLA Health Care
- Exchange
- SAFE Nasdaq
- NTLA Nasdaq
- Market Cap
- SAFE 1.2B
- NTLA 1.2B
- IPO Year
- SAFE 2017
- NTLA 2016
- Fundamental
- Price
- SAFE $16.29
- NTLA $12.06
- Analyst Decision
- SAFE Buy
- NTLA Buy
- Analyst Count
- SAFE 9
- NTLA 20
- Target Price
- SAFE $21.89
- NTLA $32.30
- AVG Volume (30 Days)
- SAFE 405.8K
- NTLA 4.2M
- Earning Date
- SAFE 10-27-2025
- NTLA 08-07-2025
- Dividend Yield
- SAFE 4.35%
- NTLA N/A
- EPS Growth
- SAFE N/A
- NTLA N/A
- EPS
- SAFE 1.43
- NTLA N/A
- Revenue
- SAFE $393,596,000.00
- NTLA $52,857,000.00
- Revenue This Year
- SAFE $0.59
- NTLA $8.32
- Revenue Next Year
- SAFE $5.06
- NTLA N/A
- P/E Ratio
- SAFE $11.37
- NTLA N/A
- Revenue Growth
- SAFE 2.22
- NTLA 14.99
- 52 Week Low
- SAFE $13.43
- NTLA $5.90
- 52 Week High
- SAFE $28.80
- NTLA $23.76
- Technical
- Relative Strength Index (RSI)
- SAFE 59.50
- NTLA 60.10
- Support Level
- SAFE $15.84
- NTLA $11.29
- Resistance Level
- SAFE $16.40
- NTLA $12.46
- Average True Range (ATR)
- SAFE 0.43
- NTLA 0.56
- MACD
- SAFE 0.04
- NTLA 0.12
- Stochastic Oscillator
- SAFE 80.77
- NTLA 84.85
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.